ABSTRACT A study was conducted in Brazil to evaluate the efficacy of danofloxacin 18% (Advocin 180TM Pfizer Inc.), in the treatment of infectious diseases in cattle including respiratory disease, enteritis, metritis or omphalitis. The clinical cases were scored as: 0 - normal; 1 - mild; 2 - moderate; 3 - severe. Animals with scores of 0 or 3 were not included in the study. On Day 0, animals with scores 1 and 2 received a SC injection of danofloxacin 18% (6 mg/kg). On Day 2, the animals were clinically scored as above and the cured animals (score 0) were removed from the study. Non-responder animals (same score or higher than Day 0 score) received a second injection of danofloxacin 18%. On Day 4, the animals were re-examined and the study finished. Before treatment on Day 0, fecal samples and nasal, vaginal and navel swabs, as appropriate to the disease, were collected for bacterial isolation and bacterial sensitivity testing using "Sensidisc" containing 5 mcg of danofloxacin. A total of 1,019 cattle were treated from which, 966 (94.8%) responded to the treatment, and 857 (84.1%) were cured: 52.4% with a single dose and 31.7% with two doses. The cure rates in each clinical category were: Respiratory disease = 79.8%; enteritis = 92.6%; metritis = 76.5% and omphalitis = 88.0%. A total of 805 bacterial isolates were obtained, of which 70.4% were sensitive, 20.0% partially sensitive and, 9.6% were resistant to danofloxacin. Danofloxacin 18% was safe and very effective in the treatment of naturally occurring infectious diseases in cattle. 18 Advocin TM Inc., Inc Inc. , Inc.) normal mild moderate severe 6 ( mg/kg. mgkg mg/kg . mg kg mg/kg) Nonresponder Non responder same 4 reexamined re examined finished nasal swabs Sensidisc "Sensidisc 1019 019 1,01 96 94.8% 948 94 8 (94.8% 85 84.1% 841 84 (84.1% 524 52 52.4 317 31 7 31.7 doses 79.8% 798 79 92.6% 926 92 765 76 76.5 880 88 88.0% 80 obtained 704 70 70.4 200 20 20.0 9 9.6 101 01 1,0 94.8 (94.8 84.1 (84.1 52. 31. 79.8 92.6 76. 88.0 70. 20. 9. 10 1, 94. (94. 84. (84. 79. 92. 88. (94 (84 (9 (8
RESUMO Um estudo foi realizado no Brasil para avaliar a eficácia de danofloxacin 18% (Advocin 180® - Pfizer Inc.), no tratamento de doença respiratória, enterite, metrite e onfalite em bovinos. Os casos clínicos foram classificados conforme a severidade em escores: 0 - normal; 1 - leve; 2 - moderado; 3 - severo. Os animais com escore 0 ou 3 não foram incluídos no estudo. No dia 0, os animais com escores 1 ou 2 receberam uma injeção SC de danofloxacin 18% (6 mg/kg). No dia 2, os animais foram reexaminados e aqueles curados (escore 0), foram removidos do estudo. Os animais que não responderam ao tratamento (escore ≥ dia 0) receberam uma segunda injeção de danofloxacin 18%. No dia 4, os animais foram reexaminados e o estudo terminado. Antes do tratamento no dia 0, foram coletadas amostras de fezes ou de secreções nasais, vaginais ou umbilicais para isolamento bacteriano e testes de sensibilidade bacteriana usando-se "Sensidisc" contendo 5 mcg de danofloxacin. Foram tratados 1.019 bovinos, dos quais, 966 (94,8%) responderam ao tratamento e 857 (84,1%) chegaram a cura: 52,4% com dose única e 31,7% com duas doses. As taxas de cura por doença foram: doença respiratória = 79,8%; enterite = 92,6%; metrite = 76,5% e onfalite = 88,0%. Um total de 805 bactérias foram isoladas, das quais 70,4% eram sensíveis, 20,0% parcialmente sensíveis e 9,6% eram resistentes ao danofloxacin. Danofloxacin 18% foi seguro e altamente efetivo no tratamento de doenças infecciosas de ocorrência natural em bovinos. 18 Advocin 180 Inc., Inc Inc. , Inc.) bovinos normal leve moderado severo 6 ( mg/kg. mgkg mg/kg . mg kg mg/kg) 4 terminado nasais usandose usando se Sensidisc "Sensidisc 1019 019 1.01 96 94,8% 948 94 8 (94,8% 85 84,1% 841 84 (84,1% 524 52 52,4 317 31 7 31,7 doses 79,8% 798 79 92,6% 926 92 765 76 76,5 880 88 88,0% 80 isoladas 704 70 70,4 200 20 20,0 9 9,6 101 01 1.0 94,8 (94,8 84,1 (84,1 52, 31, 79,8 92,6 76, 88,0 70, 20, 9, 10 1. 94, (94, 84, (84, 79, 92, 88, (94 (84 (9 (8